SelSym Biotech Inc., founded in 2019, is a pioneering biotechnology company focused on developing synthetic platelet technologies to manage hemorrhage and enhance wound healing. Co-founded by academic researchers from North Carolina State University, Georgia Tech, and the University of Virginia, the company is headquartered in Raleigh, North Carolina. Their flagship product, SymClot, is designed to address unmet clinical needs related to bleeding control in both traumatic and surgical scenarios. As of the recent funding round announcements, SelSym Biotech has successfully raised significant grants and is involved in ongoing research collaborations.
Attribute | Information |
---|---|
Founding Date | 2019 |
Headquarters | Raleigh, North Carolina, USA |
Founders | Ashley Brown, Andrew Lyon, Tom Barker |
Revenue | N/A |
Profits | N/A |
Key Investors | National Institutes of Health, Department of Defense |
Industry | Biotechnology |
Number of Employees | 2-10 |
SelSym Biotech was conceived out of a collaborative effort among researchers at NC State, Georgia Tech, and the University of Virginia, keen to address the critical demand for improved bleeding control methods. Recognizing the limitations of natural platelet transfusions due to their short shelf life and storage requirements, the founding team spearheaded the development of synthetic platelet analogs. This innovation, named SymClot, utilizes hydrogel-based particles to mimic the function of natural platelets, promising longer shelf life and easier logistics.
SelSym Biotech employs a unique approach to treating hemorrhage by using synthetic hydrogels that emulate platelet function, known as PLPs. This technology is scalable, allowing mass production that aligns with global health needs. Major achievements include:
SelSym Biotech continues to refine its synthetic platelet technology, with a focus on achieving FDA approval for clinical use. The company is strategically positioned within the biotechnology sector to address a multi-billion-dollar market for bleeding management solutions. SelSym’s competitive advantage lies in its innovative biomimetic approach, offering a potential substitute for natural platelet transfusions that can save lives in critical care settings.
SelSym Biotech stands at the forefront of bleeding management innovation with its synthetic platelet technology, SymClot. As the company moves toward clinical trials, its impact on healthcare, particularly in trauma medicine and surgical procedures, could be transformative. The focus on scalability and viability demonstrates a strong potential to meet global demands, placing SelSym in a promising position within the biotech industry. The company's journey reflects a commitment to breakthrough science with the promise of far-reaching medical advancements.